KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gross Profit (2021 - 2025)

Historic Gross Profit for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Q3 2025 value amounting to $65.3 million.

  • Aurinia Pharmaceuticals' Gross Profit rose 575.84% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236.4 million, marking a year-over-year increase of 2294.69%. This contributed to the annual value of $206.9 million for FY2024, which is 2820.93% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Gross Profit stood at $65.3 million, which was up 575.84% from $62.9 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Gross Profit high stood at $65.3 million for Q3 2025, and its period low was $866000.0 during Q1 2021.
  • In the last 5 years, Aurinia Pharmaceuticals' Gross Profit had a median value of $39.9 million in 2023 and averaged $38.1 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Gross Profit surged by 4960000.0% in 2021 and then tumbled by 1047.4% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Gross Profit (Quarter) stood at $22.9 million in 2021, then increased by 18.1% to $27.1 million in 2022, then surged by 46.64% to $39.7 million in 2023, then skyrocketed by 36.81% to $54.3 million in 2024, then increased by 20.21% to $65.3 million in 2025.
  • Its Gross Profit stands at $65.3 million for Q3 2025, versus $62.9 million for Q2 2025 and $53.9 million for Q1 2025.